Literature DB >> 12815064

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.

Alexei F Kisselev1, Margarita Garcia-Calvo, Herman S Overkleeft, Erin Peterson, Michael W Pennington, Hidde L Ploegh, Nancy A Thornberry, Alfred L Goldberg.   

Abstract

Proteasomes are the primary sites for protein degradation in mammalian cells. Each proteasome particle contains two chymotrypsin-like, two trypsin-like, and two caspase-like proteolytic sites. Previous studies suggest a complex network of allosteric interactions between these catalytic and multiple regulatory sites. We used positional scanning combinatorial substrate libraries to determine the extended substrate specificity of the caspase-like sites. Based on this analysis, several new substrates were synthesized, the use of which confirmed earlier observations that caspase-like sites (often termed postglutamyl peptide hydrolase) cleave after aspartates better than after glutamates. Highly selective inhibitors of the caspase-like sites were also generated. They stimulated trypsin-like activity of yeast 20 S proteasomes up to 3-fold but not when binding of the inhibitor to the caspase-like sites was prevented in a mutant carrying an uncleaved propeptide. Although substrates of the caspase-like sites allosterically inhibit the chymotrypsin-like activity, inhibitors of the caspase-like sites do not affect the chymotrypsin-like sites. Furthermore, when caspase-like sites were occupied by the uncleaved propeptide or inhibitor, their substrates still inhibited the chymotrypsin-like activity. Thus, occupancy of the caspase-like sites stimulates the trypsin-like activity of proteasomes, but substrates of the caspase-like sites inhibit the chymotrypsin-like activity by binding to a distinct noncatalytic site.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12815064     DOI: 10.1074/jbc.M303725200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  The origin of proteasome-inhibitor resistant HLA class I peptidomes: a study with HLA-A*68:01.

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2011-10-03       Impact factor: 5.911

2.  Amyloid β-induced FOXRED2 mediates neuronal cell death via inhibition of proteasome activity.

Authors:  SangMi Shim; WonJae Lee; HaeWon Chung; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2010-10-23       Impact factor: 9.261

Review 3.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

4.  The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring.

Authors:  Tatos Akopian; Olga Kandror; Ravikiran M Raju; Meera Unnikrishnan; Eric J Rubin; Alfred L Goldberg
Journal:  EMBO J       Date:  2012-01-27       Impact factor: 11.598

5.  A novel class of intrinsic proteasome inhibitory gene transfer peptides.

Authors:  Molly E Martin; Kevin G Rice
Journal:  Bioconjug Chem       Date:  2007-12-21       Impact factor: 4.774

Review 6.  The RNA exosome and proteasome: common principles of degradation control.

Authors:  Debora L Makino; Felix Halbach; Elena Conti
Journal:  Nat Rev Mol Cell Biol       Date:  2013-08-29       Impact factor: 94.444

7.  The ubiquitin ligase Hul5 promotes proteasomal processivity.

Authors:  Sharon Aviram; Daniel Kornitzer
Journal:  Mol Cell Biol       Date:  2009-12-14       Impact factor: 4.272

8.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.

Authors:  Matthew Britton; Marcella M Lucas; Sondra L Downey; Michael Screen; Alexandre A Pletnev; Martijn Verdoes; Robert A Tokhunts; Omar Amir; Ayrton L Goddard; Philip M Pelphrey; Dennis L Wright; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2009-12-24

9.  UBL domain of Usp14 and other proteins stimulates proteasome activities and protein degradation in cells.

Authors:  Hyoung Tae Kim; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-28       Impact factor: 11.205

10.  Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.

Authors:  Dharminder Chauhan; Ajita V Singh; Bryan Ciccarelli; Paul G Richardson; Michael A Palladino; Kenneth C Anderson
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.